icon Loading...

Innovative options for the treatment of suspected MI

thumbnail thumbnail

Therapies


Asprihale indication is to "Reduce the risk of vascular mortality in patients with suspected acute myocardial infarction (MI)"

A patient administered, portable single use device and capsules that enables oral inhalation of aspirin upon onset of MI symptoms** ( not for daily use)

Kit containing Dry powder inhaler device and drug is small enough to be carried comfortably in a pocket (smaller than an EpiPen)

  • icon

    The immediate self-administration of Asprihale® is an improvement for emergency use for patients over oral chewable aspirin, which is the current standard-of-care for suspected acute MI.

  • icon

    Inhalation via the Asprihale delivery device improves speed of aspirin bioavailability, due to bypassing first pass metabolism and the proximity of the lungs to the heart.

  • icon

    Inhaled aspirin reaches peak bioavailability in ~2 minutes, which has been shown to consistently and dramatically reduce thromboxane B 2 levels, and inhibit platelet aggregation resulting in a more potent, prompt, and predictable pharmacodynamic (PD) response.

  • icon

    A 1.5 fold greater maximum serum concentration (Cmax) of acetylsalicylic acid (ASA) is achieved within 2 minutes when delivered with ASPRIHALE Arachidonic acid induced platelet aggregation is completely and irreversibly inhibited with ASPRIHALE within ~2 minutes post dose, and maintained for 24 hours post treatment.

  • icon

    The effects of Asprihale® are a distinctly more prompt, potent, and predictable PD response than the current standard-of-care.

  • icon

    A 1.5 fold greater maximum serum concentration (Cmax) of aspirin within ~2 minutes when delivered with Asprihale, which is similar to IV administration.

mail-icon

Get in touch with us for more info about OtiTopic, Inc.